Last week in Geneva, Switzerland, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the Johns Hopkins University released a set of policy briefs that provide actionable recommendations for improving non-communicable disease (NCD) policy, research and patient care. The publication Addressing the Gaps in Global Policy and Research for Non-Communicable Diseases was put together by a working group of leading scholars and provides an action-based roadmap to reducing the global burden of NCDs.
In a related Huffington Post blog, Jeffrey Sturchio and Cary Adams underscored the importance of public-private partnerships to address the challenges posed by NCDs in coming years. For decades, Lilly has engaged stakeholders across the globe to improve patient outcomes for NCDs, specifically in diabetes.
Our work includes donating 800,000 vials on insulin to children in Africa, Asia and South America through the International Diabetes Federation’s Life for a Child program and our $30 million commitment to The Lilly NCD Partnership, a public-private initiative to improve patient outcomes in diabetes in Brazil, India, Mexico, and South Africa.
Through our work in The Lilly NCD Partnership, we are embracing many of the actions outlined in the IFPMA/Johns Hopkins University publication. For example in South Africa, we collaborate with the Donald Woods Foundation in the vast rural reaches of Eastern Cape Province. Through our collaboration, we are leveraging the Foundation’s existing infrastructure for HIV and tuberculosis home-based care to also assess diabetes risks, refer patients for diagnosis and treatment, and provide support to people with diabetes within their homes. More information on our work in South Africa is available here.